<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6608">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01995903</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00061126</org_study_id>
    <nct_id>NCT01995903</nct_id>
  </id_info>
  <brief_title>Developing a Discrimination Model to Diagnose ALS</brief_title>
  <official_title>Developing a Discrimination Model to Diagnose ALS Using Advanced MRI Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To combine several brain imaging techniques to develop a new diagnostic test to help with
      earlier diagnosis of amyotrophic lateral sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early diagnosis and lack of understanding of the pathophysiology of ALS remain a significant
      obstacle to making a timely intervention to help patients suffering from this fatal disease.
      We envision a future in which neuroimaging techniques will be a critical tool in the
      diagnostic work-up of ALS. Advanced neuroimaging techniques offer great potential in
      identifying central nervous system metabolite and cellular alterations in ALS. We propose an
      innovative approach to combine complementary advanced MRI techniques to interrogate brain
      chemistry (MRS), brain microstructure (DTI) and brain function (fcMRI) and develop a
      clinically relevant discriminatory disease model.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Developing a Discrimination Model to Diagnose ALS</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will measure brain fractional anisotropy (unitless) using diffusion tensor imaging of amyotrophic lateral sclerosis patients and compare these to corresponding measures in healthy control subjects as well as patients with lower motor neuron signs only.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Amyotrophic lateral sclerosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinical examination for ALS(amyotrophic lateral sclerosis)and subjects with lower motor neuron signs will be completed and these subjects will undergo MRI(magnetic resonance imaging)scans of the brain to assess neurologic conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI(magnetic resonance imaging)</intervention_name>
    <description>Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition.   The brain scans will take approximately 60 minutes to complete.</description>
    <arm_group_label>Amyotrophic lateral sclerosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older

          2. subjects with ALS(amyotrophic lateral sclerosis)

          3. healthy subjects -

        Exclusion Criteria:

          1. Active substance abuse

          2. Has co-morbid psychiatric disease

          3. Has opportunistic CNS (central nervous system)infection

          4. Has a history of head injury

          5. Has a contraindication for MRI (e.g. cardiac pacemaker, ferromagnetic or metallic
             implants.

          6. Pregnant -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Foerster, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bradley Foerster, M.D.</last_name>
    <phone>734-615-3588</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ladonna Austin, CRCC</last_name>
    <phone>734-936-8275</phone>
    <email>ladonna@umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Foerster, M.D.</last_name>
      <phone>734-615-3586</phone>
    </contact>
    <contact_backup>
      <last_name>Ladonna Austin, CCRC</last_name>
      <phone>734-936-8275</phone>
      <email>ladonna@umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bradley Foerster, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Bradley Foerster M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
